DMAC - NASDAQ
DiaMedica Therapeutics Inc.
$5.70
-1.2%DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
At a Glance
Live SnapshotDiaMedica Therapeutics Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
DiaMedica Therapeutics Inc. Cash Flow Statement
DMAC • NASDAQ
| DiaMedica Therapeutics Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-32.8M | -24.4M | -19.4M | -13.7M | -13.6M | -12.3M | -10.6M | -5.7M | -4.3M | -2.2M | -1.4M | -4.8M | -7.4M | -10.1M | -6.6M | -4.3M | -2.4M | -1.9M | -2.3M | -778K | |
-899K | 39K | 30K | 25K | 24K | 21K | 21K | 15K | 4K | 2.2K | 4.1K | 2.5K | 1.1M | 2.4M | 2.3M | 1.7M | 30.2K | 26.7K | 18.4K | 3.3K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -74K | 0.0 | 84.6K | -169.9K | 21.5K | -343.3K | -704.6K | -1M | 0.0 | -218.3K | -252.4K | -155.3K | 0.0 | 0.0 | |
3.8M | 2.1M | 1.7M | 1.5M | 1.6M | 1.8M | 1.2M | 620K | 409K | 263.3K | 125.5K | 343.3K | 704.6K | 1M | 0.0 | 294.5K | 252.4K | 155.3K | 0.0 | 0.0 | |
82K | -1.3M | -1.2M | 53K | 219K | 48K | 49K | 39K | -93.6K | 22.9K | -21.5K | 621.6K | 734.4K | 1M | 832.6K | 294.5K | 294.1K | 318.8K | 958.9K | 0.0 | |
(28K) | (26K) | (33K) | (27K) | (28K) | (36K) | (26K) | (80K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
675K | 1.5M | 93K | 585K | -461K | 1.2M | 387K | -636K | -44K | -918.5K | -53K | 438K | 66.6K | 1.2M | 36.2K | -148.9K | -35.6K | 41.7K | 142.9K | -26.5K | |
-29.1M | -22.1M | -18.7M | -11.5M | -12.3M | -9.2M | -9.1M | -5.7M | -3.9M | -3M | -1.4M | -3.8M | -5.5M | -5.5M | -3.4M | -2.4M | -2.1M | -1.5M | -1.2M | -801.2K | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-40K | -25K | -24K | -81K | -22K | -47K | -2K | -50K | -22K | -6.9K | -5.4K | -31.3K | -134.3K | -63.4K | -79.3K | -57.8K | -92.1K | -85.3K | -296.2K | -108.9K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (13K) | (0.0) | (0.0) | (1.5K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (148.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-59.3M | -50.4M | -69.4M | -45.7M | -69.8M | -39.7M | -12.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
57.1M | 59M | 51.1M | 57.3M | 49.3M | 23.6M | 9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 2K | 16K | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | -31.0 | -116.0 | -59.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-2.2M | (8.6M) | -18.3M | (11.5M) | -20.5M | -16.1M | -3.9M | -50K | -22K | -6.9K | -5.4K | -31.3K | -134.3K | -63.4K | -79.3K | -57.6K | -92.1K | -85.3K | -296.2K | -108.9K | |
FINANCING ACTIVITIES | ||||||||||||||||||||
44.3M | 11.7M | 36.8M | 0.0 | 29.8M | 28.8M | 0.0 | 20.6M | 2.9M | 4.1M | 1.5M | 1.6M | 5.9M | 0.0 | 3.2M | 1.8M | 0.0 | 1.2M | 4.7M | 905.9K | |
-10K | -9K | -6K | -6K | -6K | -5K | -5K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-400K | 256K | 0.0 | 0.0 | 244K | 45K | 75K | 650K | 622K | 470.6K | -22.6K | 152.5K | 95.4K | 5.2M | 211.6K | 2.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
43.9M | 12M | 36.8M | -6K | 30.1M | 28.8M | 70K | 21.2M | 3.5M | 4.6M | 1.4M | 1.7M | 6M | 5.2M | 3.4M | 4.6M | 0.0 | 1.2M | 4.7M | 905.9K | |
CASH FLOW SUMMARY | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 67.4K | 7.7K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
12.6M | -1.5M | -185K | 21K | -2.7M | 3.5M | -12.9M | 15.5M | -383K | 1.6M | -4.8K | -2.1M | 335.1K | -382K | -126.9K | 2.2M | -2.2M | -381.4K | 3.2M | -4.2K | |
3M | 4.5M | 4.7M | 4.7M | 7.4M | 3.9M | 16.8M | 1.4M | 1.7M | 166.1K | 170.5K | 2.3M | 2.2M | 2.7M | 2.8M | 659.1K | 2.9M | 2.8M | 317.3K | 273.8K | |
15.6M | 3M | 4.5M | 4.7M | 4.7M | 7.4M | 3.9M | 16.8M | 1.4M | 1.7M | 165.7K | 203.8K | 2.5M | 2.3M | 2.7M | 2.8M | 629.5K | 2.5M | 3.5M | 269.6K | |
-29.1M | -22.1M | -18.8M | -11.6M | -12.3M | -9.2M | -9.1M | -5.7M | -3.9M | -3M | -1.4M | -3.8M | -5.6M | -5.5M | -3.5M | -2.4M | -2.2M | -1.6M | -1.5M | -910.1K |
SEC Filings
DMAC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 18, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 |
Related Guides
Continue your DMAC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.